Probability of death as a function of the number of months after randomisation in the National Emphysema Treatment Trial comparing medical therapy (––––)

Slides:

Advertisements

Similar presentations

Long-Term Follow-Up of Patients Receiving Lung-Volume-Reduction Surgery Versus Medical Therapy for Severe Emphysema by the National Emphysema Treatment.

Advertisements

Long-Term Follow-Up of Patients Receiving Lung-Volume-Reduction Surgery Versus Medical Therapy for Severe Emphysema by the National Emphysema Treatment.

The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.

Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small.

Level of physical activity by Global Initiative for Obstructive Lung Disease (GOLD) stage, BODE (body mass index, FEV1 for airflow obstruction, dyspnoea,

Changes in operating lung volumes expressed as % of predicted total lung capacity (%TLC predicted) are shown as minute ventilation (V′E) increases during.

Treatment algorithm for managing chronic thromboembolic pulmonary hypertension (CTEPH), from the European Society of Cardiology/European Respiratory Society.

Kaplan–Meier analysis of survival over 2 years of treatment with riociguat in the CHEST-2 study [54]. Kaplan–Meier analysis of survival over 2 years of.

Axial computed tomography (CT) images a) at baseline and b) at a 12-month follow-up scan, in a patient with idiopathic pulmonary fibrosis (IPF). b) Note.

Extent of interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD. A simple stratification that utilises pulmonary function.

The distribution of the extent of change in inspiratory capacity (IC) during exercise is shown in moderate-to-severe chronic obstructive pulmonary disease.

Representative diaphragm electromyogram (EMG) tracings at rest (a and b) and during maximum voluntary ventilation (c and d) in a healthy subject (a and.

Changes in operating lung volumes are shown as ventilation increases with exercise in a) age-matched normal subjects (n = 25) and b) chronic obstructive.

Serial computed tomography (CT) imaging for monitoring disease progression in patients with idiopathic pulmonary fibrosis. Serial computed tomography (CT)

Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.

Prevalence of chronic bronchitis in relation to active smoking, stratified by age. □: nonsmokers; ▒: 1–10 cigarettes per day; ░: 11–20 cigarettes per day;

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

Benefit–risk balance and its individual determinants with personalised chronic obstructive pulmonary disease (COPD) treatment choices. Benefit–risk balance.

Evaluation of cognitive performance based on the ability to copy a simple drawing. Evaluation of cognitive performance based on the ability to copy a simple.

Profile of Pseudomonas aeruginosa resistance by country and antibiotic

The projected numbers of tobacco-related deaths between 2000–2035 in millions for a) the world and b) medium- and low-income countries (top) and high-income.

Forest plot comparison of mucolytics versus placebo for the number of exacerbations per patient per month. Forest plot comparison of mucolytics versus.

Elastic staining of paraffin-embedded lung tissue.

The changing distribution of endothelin (ET)A and ETB subtypes with decreasing vessel diameter. a) ET-1 binding and b) distribution of ETA and ETB receptors.

Mean change from baseline in 6-min walking distance (6MWD) in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial.

Proteinase activated receptor-1 expression in a) weak immunostaining in normal lung tissue, b) intense immunostaining in idiopathic pulmonary fibrosis,

Kaplan–Meier curves for the probability of a first adjudicated primary end-point event in the AMBITION trial, suggesting that the primary outcome events.

Survival in patients with pulmonary arterial hypertension based on aetiology. •: congenital heart disease; ▪: collagen vascular disease; ▵: HIV-related;

Change in forced vital capacity (FVC) % predicted (% pred) per week from baseline in the CAPACITY 004 and 006 study comparing pirfenidone (2403 mg·day−1)

Incidence of chronic obstructive pulmonary disease according to the history of chronic cough/phlegm. Incidence of chronic obstructive pulmonary disease.

Number of ventilator-associated pneumonia (VAP) patients with newly isolated micro-organisms from endotracheal aspirates after initiation of antibiotic.

Proportion of patients in each World Health Organization functional class (WHO-FC) at the time of pulmonary arterial hypertension-associated systemic sclerosis.

Exertional dyspnoea intensity is shown relative to a) work rate and b) diaphragm electromyography relative to maximum (EMGdi/EMGdi,max) during incremental.

Duration of antibiotic therapy according to clinical pulmonary infection score in a randomised trial of an antibiotic discontinuation policy for clinically.

Cumulative survival estimates for the subgroup of 127 patients with ventilator-associated pneumonia caused by nonfermentative Gram-negative bacilli according.

Effects of N-acetylcysteine (▒) and placebo (░) on vital capacity (VC) and diffusing capacity of the lung for carbon monoxide (DL,CO) depending on baseline.

Exposure to intermittent hypoxia after 13 nights led to an increase in sympathetic activity measured by muscle sympathetic nerve activity (MSNA). Exposure.

The effect of inhaled tiotropium (18 μg once daily) on the improvement in treadmill exercise endurance time in patients with chronic obstructive pulmonary.

Kaplan–Meier survival curves for baseline cardiac magnetic resonance imaging variables according to the median value in patients with pulmonary hypertension.

Survival of idiopathic pulmonary arterial hypertension (IPAH) patients in World Health Organization functional class (FC) at baseline IV is extremely poor.

Kaplan–Meier plots for a) clinical worsening and b) survival in the overall population during the Chronic Thromboembolic Pulmonary Hypertension Soluble.

Cumulative mortality over 60 months in patients with α1-antitrypsin deficiency and an initial forced expiratory volume in 1 s

A) Inspiratory capacity (IC) in asthmatics with (n=13) and without (n=7) expiratory flow limitation (EFL) at various levels of exercise, expressed as a.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (○) 1 mg and 2.5 mg compared with inhaled nitric oxide (•) in patients.

Distribution of systolic pulmonary artery pressure (Ppa) in relation to functional class (FC) for congenital heart disease patients with a) atrial septal.

Effect of omalizumab (n = 209) on a) clinically significant and b) severe exacerbation rates, compared with placebo (n = 210). #: adjustment due to a pre-study.

Forest plot from meta-analysis carried out on four studies including high-dose N-acetylcysteine (NAC) treatment a) assessing the relative risk of chronic.

Correlation between inspiratory capacity (IC)/total lung capacity (TLC) ratio and oxygen pulse at peak exercise in chronic obstructive pulmonary disease.

Survival rates in older (>65 years) compared with younger (18–65 years) patients with idiopathic pulmonary arterial hypertension. a) Expected ( )

Kaplan-Meier curves for overall survival in patients with adenocarcinoma and time since first-line therapy of

Clinical findings in patients with chronic obstructive pulmonary disease according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD)

Effect of pulmonary arterial hypertension-specific treatment on systemic inflammation. a) Kaplan–Meyer survival curves for patients normalising their C-reactive.

Kaplan–Meier curve for progression-free survival for gefitinib versus doublet chemotherapy in three phase III trials in first-line nonsmall cell lung cancer.

Reduction in mean pulmonary vascular resistance (PVR) in 37 subjects following acute sildenafil administration to ongoing bosentan therapy in the COMPASS-1.

Kaplan–Meier curve for progression-free survival for non-Asian patients with epidermal growth factor receptor (EGFR) mutation-positive status in the INTEREST.

A) Operating lung volumes and b) breathing frequency (Fb) during incremental cycle exercise in patients with moderate chronic obstructive pulmonary disease.

Left upper lobe complete atelectasis 2 days after implantation of four endobronchial valves into the left upper lobe in a patient with emphysema. a) Chest.

24-h blood pressure profile after a, d) one night of intermittent hypoxia (IH) exposure, b, e) 13 nights IH exposure and c, f) 5 days after cessation of.

Endobronchial valve (EBV) treatment for emphysema, summary of treatment selection and outcome. Endobronchial valve (EBV) treatment for emphysema, summary.

Interventional bronchoscopic and surgical treatments for chronic obstructive pulmonary disease (COPD). Interventional bronchoscopic and surgical treatments.

Mean change from baseline in percentage predicted forced vital capacity (FVC) in the a) phase III CAPACITY [27] and b) ASCEND [14] studies. #: n=174; ¶:

Drugs that target the prostacyclin pathway and their routes of administration. #: approved only by the US Food and Drug Administration; ¶: approved only.

Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy.

Flow–volume loops of test breaths and preceding control breaths of a representative chronic obstructive pulmonary disease patient with different degrees.

Flow–volume loops of test breaths and preceding control breaths of three representative chronic obstructive pulmonary disease patients with different degrees.

Treatment algorithm for chronic thromboembolic pulmonary hypertension.

Survival estimates of patients in REVEAL using Kaplan–Meier estimates stratified by newly versus previously diagnosed patients and survival estimated by.

Correlation between leg fluid volume (LFV) displacement measured by electrical impedance and apnoea/hypopnoea index (AHI) in non-obese obstructive sleep.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (Rio) compared with inhaled nitric oxide (NO) in patients with chronic.

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

Presentation transcript:

Probability of death as a function of the number of months after randomisation in the National Emphysema Treatment Trial comparing medical therapy (––––) versus surgery (- - - -) for patients with severe emphysema. Probability of death as a function of the number of months after randomisation in the National Emphysema Treatment Trial comparing medical therapy (––––) versus surgery (- - - -) for patients with severe emphysema. Reproduced from [22], with permission from the publisher. a) All patients (n = 1,218); b) high-risk patients (n = 140); c) non high-risk patients (n = 1,078); d) upper lobe predominance, low baseline exercise capacity (n = 290); e) upper lobe predominance, high baseline exercise capacity (n = 419); f) non upper lobe predominance, low baseline exercise capacity (n = 149); and g) non upper lobe predominance, high baseline exercise capacity (n = 220). D. Van Raemdonck, and V. Ninane Eur Respir Rev 2010;19:242-247 ©2010 by European Respiratory Society